Ibogaine Side Effects and Cardiac Risks

Published medical sources document that ibogaine side effects range from expected, acute neurological and gastrointestinal symptoms to life-threatening cardiac complications. The main documented hazards are cardiac arrhythmias, ventricular tachyarrhythmias, and prolonged cardiac repolarization. These are reported alongside deaths that occurred between 1.5 and 76 hours after ingestion in one forensic review. Individuals reported at higher risk include those with advanced preexisting cardiovascular disease, people taking concurrent medications, and people with seizures associated with withdrawal from alcohol or benzodiazepines. Expected acute reactions include transient ataxia, intention tremors, and gastrointestinal symptoms; in the MISTIC study, ataxia and tremor resolved within 24 hours.

Published evidence was reviewed as of October 27, 2026. This page is education and harm reduction information only. The Drug Enforcement Administration classifies ibogaine as a Schedule I controlled substance under federal law, under the category of hallucinogenic substances (21 CFR 1308.11, DEA code 7260). For jurisdiction-specific legal frameworks, consult our guide to where ibogaine is legal and our state-by-state legal status tool. Consult a cardiologist before any decision.

Documented Ibogaine Side Effects by Physiological System

Adverse Effect Category	Clinical Findings and Published Manifestations	Documented Risk Factors and Research Sources
Cardiac Repolarization	QT and QTc interval prolongation, bradycardia, ventricular tachyarrhythmias, and sudden cardiac arrest.	Mechanism attributed to hERG blockade in a 2016 Clinical Toxicology review; QTc prolongation and bradycardia observed in an open-label Dutch study in Addiction.
Motor and Neurological	Severe transient ataxia (Dutch study, all 14); mild ataxia and intention tremor resolving within 24 hours, and headache treated in 40% (MISTIC).	Documented in subjects across the 2022 Dutch study and the 2024 Stanford MISTIC study in Nature Medicine.
Gastrointestinal	Nausea requiring treatment in 7 of 30 MISTIC participants (23%); the 2022 systematic review lists gastrointestinal events among acute (<24 h) effects.	7 of 30 (23%) MISTIC participants were treated for nausea (Nature Medicine); a 2022 systematic review in Psychopharmacology classes gastrointestinal events among acute effects.
Psychiatric Disturbances	Rare occurrences of mania or psychosis.	Documented in a 2024 primary-care clinical primer published in the American Journal of Therapeutics.
Fatal Outcomes and Comorbidities	Preexisting medical conditions and/or commonly abused substances explained or contributed to death in 12 of 14 cases with adequate postmortem data.	Identified in a forensic study of 19 fatalities in the Journal of Forensic Sciences.
Metabolic Complications	CYP2D6 polymorphism can influence blood concentrations of ibogaine and noribogaine, which may matter when other CYP2D6-metabolized medications are taken.	Polymorphism and blood concentrations: 2016 Clinical Toxicology review; phenotype assessment and QT-drug screening would be required per a 2026 Cureus review.

Cardiac Risks: QT Prolongation and Arrhythmia

Cardiac complications are the main hazard reported in the published literature (QTc prolongation was the most common acute cardiac event in the 2022 systematic review). A 2015 review by Koenig and Hilber in Molecules noted that alarming reports of life-threatening complications and sudden deaths temporally associated with ibogaine have accumulated. These adverse reactions were hypothesised to be associated with ibogaine's propensity to induce cardiac arrhythmias. Blockade of human ether-a-go-go-related gene (hERG) potassium channels is reported to delay cardiac repolarization.

A 2016 literature review published in Clinical Toxicology reported that this channel blockade delays repolarization and prolongs the QT interval, creating vulnerability to ventricular tachyarrhythmias and sudden cardiac arrest. The authors documented 27 fatalities following ingestion across the medical literature they surveyed. They also presented eight case reports that suggest ibogaine caused ventricular tachyarrhythmias and QT interval prolongation in individuals who had no pre-existing cardiovascular conditions or family history.

An open-label observational study published in Addiction (2022) reported clinically relevant cardiac changes. Researchers monitored 14 patients with opioid use disorder for at least 24 hours following ibogaine administration. The maximum Fridericia-corrected QT (QTc) prolongation averaged 95 milliseconds, ranging from 29 to 146 milliseconds. Fifty percent of participants reached a QTc exceeding 500 milliseconds, and prolongation above 450 milliseconds persisted beyond 24 hours in 6 of the 14 subjects. Although no torsades de pointes occurred, the authors concluded that ibogaine can induce clinically relevant but reversible QTc prolongation, bradycardia, and severe ataxia.

A 2022 systematic review of 18 studies by Ona et al. in Psychopharmacology categorized adverse events into acute reactions occurring within 24 hours and longer-lasting effects. QTc prolongation emerged as the most common acute cardiac alteration across clinical reports, though the review notes that causation cannot be clearly established because most of the studies are case reports or uncontrolled. A 2024 primer in the American Journal of Therapeutics stated that fatal arrhythmias may occur without rigorous cardiac screening.

Fatalities and Documented Preexisting Comorbidities

In a 2012 forensic analysis published in the Journal of Forensic Sciences, Alper et al. examined all known fatalities outside West Central Africa between 1990 and 2008. The study identified 19 individuals, comprising 15 men and four women between 24 and 54 years of age, who died within 1.5 to 76 hours of taking ibogaine.

Postmortem data revealed that advanced preexisting medical comorbidities, predominantly cardiovascular disease, or commonly abused substances explained or contributed to death in 12 of the 14 cases where adequate autopsy records were available. Alper et al. also identified seizures associated with withdrawal from alcohol and benzodiazepines, alongside the uninformed use of ethnopharmacological preparations, as other apparent risk factors for death.

The 2016 review in Clinical Toxicology concluded that, with limited medical supervision, more ibogaine-related deaths are likely, particularly in people with preexisting cardiac conditions and people taking concurrent medications. See our guides to ibogaine and ibogaine for alcoholism.

Neurological, Gastrointestinal, and Psychiatric Effects

Beyond cardiovascular hazards, ibogaine was followed by acute motor, neurological, and gastrointestinal effects in clinical reports. In the 2022 Dutch open-label observational study in Addiction, severe transient ataxia resulting in the inability to walk without support occurred in all 14 participants.

The 2024 Stanford MISTIC prospective observational trial, published by Cherian et al. in Nature Medicine and archived in PubMed Central, examined 30 male Special Operations Forces veterans with predominantly mild traumatic brain injury (TBI). All 30 participants developed transient mild ataxia and intention tremors that resolved within 24 hours. Additionally, 12 participants (40%) received medical treatment for headache, and 7 participants (23%) required treatment for nausea.

The 2024 clinical primer in the American Journal of Therapeutics noted that expected transient effects include ataxia, tremors, and gastrointestinal symptoms. That primer also reports rare mania or psychosis. Mention any psychiatric history to the clinician you consult. See also our guide to ibogaine vs ayahuasca.

Drug Interactions and CYP2D6 Metabolism

As detailed in the 2016 Clinical Toxicology review, the human body metabolizes ibogaine primarily via the cytochrome P450 2D6 (CYP2D6) enzyme into its primary metabolite, noribogaine. Genetic polymorphisms in the CYP2D6 enzyme can influence blood concentrations of both ibogaine and noribogaine.

These metabolic variations carry safety implications when patients take other medications processed by CYP2D6. A 2026 narrative review in Cureus on pharmacy practice in Japan said that, if ibogaine were approved, it would require CYP2D6 metabolizer phenotype assessment, mandatory screening for QT-prolonging drug interactions, and cardiac monitoring.

The 2024 American Journal of Therapeutics primer says ibogaine may have dangerous interactions with opiates, so patients treated for opioid use disorder must withdraw from long-acting opioids. Alper et al. named seizures associated with withdrawal from alcohol and benzodiazepines as an apparent risk factor for death. Ask a clinician about any medication or substance you use. Our psychedelic medication safety guide and medication safety checker give general background. Ask a cardiologist or clinician about your own medications.

Clinical Monitoring Protocols and Research Trials

In the Stanford MISTIC study, Cherian et al. administered intravenous magnesium sulfate alongside ibogaine to 30 male Special Operations Forces veterans. The authors noted that while ibogaine has been associated with instances of fatal cardiac arrhythmia, coadministration of magnesium may mitigate this concern.

The MISTIC protocol used continuous 5-lead ECG monitoring for 12 to 16 hours following ibogaine administration to track QTc visually, alongside blood pressure and pulse oximetry monitoring. Intravenous magnesium sulfate was administered before treatment and repeated approximately 12 hours later. Under this protocol, researchers detected no instances of bradycardia, tachycardia, clinically meaningful QT prolongation (judged by visual ECG monitoring), or hemodynamic instability, and no unexpected or serious adverse events occurred. However, the study authors emphasized that their findings derived from an open-label observational design and explicitly called for controlled clinical trials.

Texas enacted Senate Bill 2308 (89th Legislature, regular session, author Parker), which was signed by the Governor on June 11, 2025 and took effect immediately, as recorded in the legislative record and bill history.

Senate Bill 2308 adds Chapter 491 to the Texas Health and Safety Code. It directs the Health and Human Services Commission to enter an interagency contract with the lead institution of higher education of the selected consortium to fund its ibogaine drug development clinical trials. The statute explicitly specifies that the commission may not disburse funds to a consortium until it verifies the receipt of matching funds from non-state sources. For background on clinical applications under study, review our guide on ibogaine for opioid addiction.

Questions to Ask a Cardiologist or Clinician

Anyone evaluating published ibogaine research or considering participation in clinical studies must consult a licensed physician and a cardiologist. Tell the cardiologist about your medical history and any substances or medications you use.

Bring these questions to a cardiologist or clinician:

• Do my personal and family cardiac history, or any prior ECG results, raise concerns about QT interval or rhythm?
• Which of my medications or supplements affect heart rhythm, and which are processed by the same liver enzyme (CYP2D6)?
• What heart monitoring would be expected, for how long, and who would respond to an abnormal reading?
• Do I have a history of seizures, or am I using or withdrawing from alcohol, benzodiazepines or opioids, and what does that mean for risk?
• Would my electrolyte levels (potassium, magnesium) need checking, and why?
• Is this being offered inside a regulated clinical trial with medical oversight, and what emergency capabilities are on site?

Cardiac Risk Is the Main Documented Hazard of Ibogaine

Published clinical and forensic literature reports serious cardiac risk from ibogaine, mainly QT prolongation and arrhythmia. The primary safety concerns are hERG potassium-channel blockade, marked QTc prolongation, ventricular tachyarrhythmias, and documented fatalities. These severe cardiac hazards occur alongside documented acute physical effects, specifically transient ataxia, tremors, and nausea.

According to published forensic and clinical data, individuals at the highest reported risk include those with preexisting cardiovascular disease, people taking concurrent medications, and people with seizures associated with withdrawal from alcohol or benzodiazepines. The Stanford MISTIC study documented no unexpected serious adverse events in 30 participants when magnesium coadministration and continuous 12 to 16 hour 5-lead ECG monitoring were used. However, the authors called for controlled trials because the findings are open-label. A 30-person open-label study with continuous ECG monitoring does not show that use without monitoring is safe.

This verdict rests exclusively on peer-reviewed pharmacology studies (Koenig and Hilber 2015, Clinical Toxicology 2016, Addiction 2022, Ona et al. 2022, Cherian et al. 2024, Cureus 2026), forensic reviews (Alper et al. 2012), federal regulations in 21 CFR 1308.11, and Texas statutory text. Mind Medicine Law ran no experimental tests of its own on ibogaine. A screening by a cardiologist, a review of your medications with a clinician, or a regulated clinical trial with medical oversight and on-site emergency capabilities would give an individual a personal risk assessment that this page cannot give; none of them makes the risks above go away. Talk to a cardiologist before any decision.